Introduction
New Psychoactive Substances (NPS) are recreational drugs which have been developed or marketed to reproduce the effects of established, controlled drugs. There has been a dramatic increase in the availability of NPS over the last decade, 1 and this has posed a significant challenge to legislative bodies internationally to determine the best means of ensuring appropriate control of NPS.
On 26 May 2016, the UK Psychoactive Substances Act (PSA) came into force, making it a criminal offence to produce, supply, import or export any substance intended for human consumption that is capable of producing a psychoactive effect, apart from specified exempted substances, 2 punishable by up to 7 years in prison. The Act replaced the previous system of enacting temporary control of a substance using temporary class drug orders (TCDO) prior to implementing full control under the Misuse of Drugs Act, 1971 . 3 This new legislation provides more rapid control of the increasing number of NPS without the need to prove harm associated with use and is targeted at trying to decrease supply of NPS. [4] [5] [6] Overall the use of NPS is low compared with herbal cannabis which is already subject to legal controls in most countries. In England and Wales, where cannabis is a Class B controlled drug, the number of adults aged 16-59 years who report having taken cannabis in their lifetime (29.2%) is 10 times higher than the number who report having taken an NPS (2.9%). 7 However, of those who had used an NPS in the last year, two-thirds are aged 16-24 years and, as NPS are popular amongst younger users, there is concern that they may act as a gateway to the use of controlled drugs.
To understand the impact of the introduction of the PSA on the availability of MDMB-CHMICA, we assessed its availability from Internet suppliers for purchase in the UK before and after the introduction of this legislation. We chose to use MDMB-CHMICA as it has previously been shown that it is widely available from Internet suppliers and there is a high prevalence of use in the UK. 4, 6 Materials and methods Snapshot surveys of the availability of MDMB-CHMICA from the Internet were conducted using the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) methodology 8 on 7
March (pre-PSA) and 30 June (post-PSA) 2016. These dates were chosen in order that there was a sufficient interval both before and after the date of the Act's implementation (26th May).
The terms 'buy MDMB-CHMICA' and 'buy MMB-CHMINACA' were used with the search engine google.co.uk. The first 100 search results were reviewed in full followed by 'sampling to exhaustion', defined as ceasing when 20 consecutive irrelevant search results were found; identified websites were only included if there was publically available information on costs. Websites were excluded if they required a form to be submitted in order to access the prices or if the seller needed to be contacted directly. Data on the country of origin of the website, the form, quantity for sale and cost for each quantity of MDMB-CHMICA/MMB-CHMINACA were extracted.
Purchase costs were converted into US Dollars using the European Commission's Financial Programming and Budget online conversion tool 9 according to the exchange rate at the time of each survey. Median costs for each available quantity were compared using the Mann-Whitney U test on Microsoft Excel.
Ethical considerations
Only publically accessible, non-password protected websites were used for this study and no searches of the dark web were undertaken. No attempt was made to contact any supplier nor to purchase any substance from the websites. 
Discussion
Worldwide there have been various attempted solutions to this problem of how to effectively and efficiently control NPS. The US Federal Analogue Act allows control of any substance that is 'substantially similar' and has a psychoactive effect 'similar to or greater than' a controlled substance. 10 However, this requires a separate court judgement for each new substance and different courts may potentially make different judgements for the same substance. It must be noted that recently the US government has not relied on this act for the control of new synthetic cannabinoids. However, implementing a TCDO was a labour-intensive process and the responsibility lay with clinicians and researchers to produce evidence that a substance was associated with harm before it could be permanently controlled by legislation. There was also an inevitable time-lag, usually of a year or more, between an NPS being first supplied on the market, it being identified in shipments seized by police and border control agencies, collecting evidence that the substance is associated with harm and then a TCDO being implemented. During this time the NPS would be effectively legal and hence NPS came to be known generically as 'legal highs'. Our snapshot availability surveys show that MDMD-CHMICA was widely and easily available over the Internet both in March and June 2016. It appears to be very straightforward to order both small quantities for personal use (0.25 g) and very large quantities that are likely intended to be distributed to other users (5 kg or more).
The introduction of the PSA was associated with a decrease in the number of UK-based websites (reduced from 14 pre-to 2 post-legislation, 85.7% reduction) with two UK-based websites stating that they were no longer active due to the Act. Also after the introduction of the Act, six websites were found which did not openly display a postal address or domain name based in a specific country, suggesting suppliers were going to some lengths to conceal their country of origin. However, MDMB-CHMICA still appears to be easily available from non-UK-based websites with only three such websites (7.9%) displaying warnings that they did not supply customers in the UK. The reduction in websites based in the USA and appearance of several websites based in China is interesting but difficult to explain with reference to the UK PSA alone. The Act specifically prohibits the import and export of NPS in the UK but it is unlikely that this would lead to the removal of websites which are based in other countries. We are not aware of any changes in legislation in the USA or China which could explain these changes.
Our study did not demonstrate any increase in the price of the drug post-legislation. This was perhaps unexpected as increases in price have previously been demonstrated following control of other NPS under the Misuse of Drugs Act 1971 such as mephedrone. 12 This kind of study clearly carries inherent limitationsInternet supply is only one route of supply and this study does not assess availability of MDMB-CHMICA through other routes such as street dealers or high street head shops. Furthermore we only accessed publically available websites and did not conduct any searches of the 'dark web' nor did we attempt to purchase any substances from any of the websites and therefore cannot verify that these websites sold the substance as advertised. Nevertheless we used an established snapshot methodology 6, 8, 13 and used the same methodology pre-and post-the PSA. The 'blanket ban' approach of the UK PSA follows the example of several other countries which have responded to the challenge set by NPS in recent years: Ireland (2010), Poland (2011) and Romania (2012). This approach is attractive because of its simplicity but also because it ends the previous reactive approach of legislators implementing TCDO's for each NPS. However, there has been criticism of the PSA including the difficulty of defining what actually is a psychoactive substance, the potential to criminalise many benign substances which are not exempted under the Act, the potential impact it may have on medical research into psychoactive substances and the potential displacement of NPS sales to illegal networks. 14 The findings from our study are complimentary to national figures released from the UK Home Office stating that in the 3 months following the implementation of the Act, 308 high street shops have stopped selling NPS and 24 headshops have closed down altogether. 15 We believe this study is the first to look at the availability of an NPS from Internet based suppliers before and after implementation of the PSA.
